Does MEPOLIZUMAB Cause Bronchial secretion retention? 209 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 209 reports of Bronchial secretion retention have been filed in association with MEPOLIZUMAB (Nucala). This represents 0.5% of all adverse event reports for MEPOLIZUMAB.
209
Reports of Bronchial secretion retention with MEPOLIZUMAB
0.5%
of all MEPOLIZUMAB reports
1
Deaths
186
Hospitalizations
How Dangerous Is Bronchial secretion retention From MEPOLIZUMAB?
Of the 209 reports, 1 (0.5%) resulted in death, 186 (89.0%) required hospitalization.
Is Bronchial secretion retention Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 209 reports have been filed with the FAERS database.
What Other Side Effects Does MEPOLIZUMAB Cause?
Asthma (11,033)
Dyspnoea (9,192)
Wheezing (6,093)
Product dose omission issue (5,873)
Cough (4,577)
Pneumonia (4,107)
Therapeutic product effect incomplete (4,106)
Drug ineffective (3,880)
Loss of personal independence in daily activities (3,566)
Fatigue (2,656)
What Other Drugs Cause Bronchial secretion retention?
ALBUTEROL (374)
TIOTROPIUM (295)
PREDNISONE (268)
MONTELUKAST (240)
BUDESONIDE (182)
OMALIZUMAB (171)
FUROSEMIDE (169)
BISOPROLOL (163)
BUDESONIDE\FORMOTEROL (156)
ACETAMINOPHEN (151)
Which MEPOLIZUMAB Alternatives Have Lower Bronchial secretion retention Risk?
MEPOLIZUMAB vs MEPROBAMATE
MEPOLIZUMAB vs MERCAPTOPURINE
MEPOLIZUMAB vs MEROPENEM
MEPOLIZUMAB vs MEROPENEM ANHYDROUS
MEPOLIZUMAB vs MESALAMINE